Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912093 · ClinicalTrials.gov registry record · Phase 3
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 98
- Enrollment target
NCT00912093 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 98 participants.
The verdict
NCT00912093, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 98 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
Interventions
- DRUG Placebo
- DRUG Icatibant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-07-16 |
| Est. Completion | 2010-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912093
The ClinicalTrials.gov registry entry for NCT00912093 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00912093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00912093 about?
NCT00912093 is a clinical study titled "A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)". This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
What is the current status of trial NCT00912093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 98 participants. The study started on 2009-07-16. Estimated completion is 2010-10-01.
What interventions are being tested in trial NCT00912093?
The interventions under investigation include: Placebo (DRUG), Icatibant (DRUG).
Who is sponsoring clinical trial NCT00912093?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.